Trive Capital Announces Sale of EarthLink
Since Trive's investment in EarthLink in 2018 as part of a corporate carveout, the Company has transformed from a legacy DSL and email business in precipitous decline to an asset-light connectivity platform serving over 500,000 consumers and small businesses nationwide. The Company has grown and will continue to grow based on its expanded fiber and 5G internet solutions and commitment to customer service for consumers and small businesses.
"During our partnership with Trive, we have taken one of the most trusted brands in the internet space and turned it into a trusted option for consumers and small businesses nationwide," commented
About EarthLink
EarthLink is an internet service provider offering fiber and 5G internet solutions for homes and businesses nationwide. With a focus on dependable connectivity, flexible plans, and customer-focused service, EarthLink provides broadband options designed to meet the needs of modern households and businesses. EarthLink is headquartered in
About Trive Capital
Trive Capital is a Dallas, Texas based private equity firm with more than $8 billion of regulatory assets under management. Trive focuses on investing equity and debt in what it sees as strategically viable middle-market companies with the potential for transformational upside through operational improvement.
The Trive team is comprised of seasoned investment professionals who have been involved in over 250 middle-market transactions representing in excess of $10 billion in revenue across Trive's targeted industry sectors and situations.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trive-capital-announces-sale-of-earthlink-302914673.html
SOURCE Trive Capital
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Think Together Celebrates 20 Years of ASES During Lights On Afterschool at 450 Schools Across California
- LEAP Group Relaunches HumanView, a Growth Intelligence System Built to Explain Why Customers Behave the Way They Do
- Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share